Seres Therapeutics vs Regeneron
Side-by-side comparison of AI visibility scores, market position, and capabilities
Seres Therapeutics develops microbiome therapeutics, including Vowst, the first FDA-approved oral microbiome medicine for preventing recurrent C. difficile infection.
About
Seres Therapeutics is a publicly traded clinical-stage biopharmaceutical company founded in 2012 that pioneered the development of microbiome therapeutics, medicines derived from human gut microbiota. The company's lead product Vowst received FDA approval in 2023 as the first oral microbiome therapeutic, consisting of purified fecal microbiota spores administered as capsules to prevent recurrent Clostridioides difficile infection after antibiotic treatment. C. difficile infects hundreds of thousands of Americans annually and has high recurrence rates that existing antibiotics cannot fully prevent. Vowst works by restoring a diverse, healthy gut microbiome that can resist C. difficile colonization. Seres has partnered with Nestlé Health Science for US commercialization and is developing pipeline programs for inflammatory bowel disease, oncology supportive care, and other conditions where the gut microbiome plays a pathological role. The company's success with Vowst validated the regulatory pathway for microbiome therapeutics and established Seres as the pioneer of an emerging therapeutic class with broad potential across gastrointestinal and systemic diseases.
Tarrytown NY biopharma giant; creator of Dupixent (>$14B revenue), Eylea, and Kevzara. Velocity Genome platform drives fast antibody and bispecific drug discovery.
About
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized mouse technology that dramatically accelerates the discovery of human antibodies—and has used it to produce multiple best-in-class biologics across inflammatory, oncologic, and eye diseases.\n\nRegeneron's commercial portfolio is anchored by Dupixent (dupilumab), developed with Sanofi, which has become one of the best-selling drugs globally with over $14 billion in 2024 revenues, treating atopic dermatitis, asthma, COPD, and other type-2 inflammatory conditions. Additional key products include Eylea (aflibercept) for macular degeneration and PRALUENT for cardiovascular cholesterol lowering. The company's bispecific antibody pipeline, cancer vaccines in collaboration with BioNTech, and gene therapy programs represent its next growth wave.\n\nRegeneron reported over $14 billion in annual revenue in 2024 and maintains a world-class science culture, consistently ranking among the top companies for R&D productivity and employee satisfaction. Its Tarrytown campus houses more than 10,000 employees and remains a leading independent US biopharmaceutical innovator.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.